Advertisement

Topics

Novartis: Zykadia Phase III Trial Meets Primary Endpoint

01:49 EDT 23 Sep 2016 | FinanzNachrichten

BASEL (dpa-AFX) - Novartis (NVS) announced top-line results from its Phase III ASCEND-4 clinical study for Zykadia (ceritinib) in patients with advanced anaplastic lymphoma kinase-positive non-sma...

Original Article: Novartis: Zykadia Phase III Trial Meets Primary Endpoint

NEXT ARTICLE

More From BioPortfolio on "Novartis: Zykadia Phase III Trial Meets Primary Endpoint"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...